National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program - Fiscal Year 2026
ID: 75N91025R00005Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNIH NCIBethesda, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Original Source

https://sam.gov/opp/05d05cd0f1344fa590ef9793f735d636/view
Timeline
    Description

    The National Cancer Institute (NCI) within the Department of Health and Human Services is soliciting proposals for the Small Business Innovation Research (SBIR) Innovative Concept Award Program for Fiscal Year 2026. This program aims to support small businesses in developing innovative technologies for the treatment and prevention of pediatric and rare cancers, particularly those with a 5-year survival rate of less than 50%. Proposals should demonstrate technical feasibility and proof-of-concept, focusing on therapeutic technologies, diagnostic devices, or digital health tools, while also addressing the clinical problems associated with specific cancer types. Interested applicants must submit a white paper by July 11, 2025, and full proposals by October 17, 2025. For further inquiries, contact Tanya Renwick at ncioasbir@mail.nih.gov.

    Point(s) of Contact
    Tanya Renwick
    ncioasbir@mail.nih.gov
    Files
    Title
    Posted
    Amendment 1 - Questions and Answers.pdf
    The document is an amendment to Solicitation Number 75N91025R00005 issued by the National Cancer Institute (NCI). It provides additional information following a pre-proposal conference, including a recording and written responses to key questions from participants. The solicitation is specifically for Small Business Innovation Research (SBIR) awards related to the development of technologies for pediatric and rare cancers. Eligible applicants must be small for-profit businesses located in the U.S. with 500 or fewer employees. The document clarifies critical distinctions between SBIR awards and academic grants, emphasizing a focus on commercial product development. Concept Awards, which fund early-phase projects, target high-risk, transformative innovations. Applicants may submit White Papers for early feedback, and the proposal process includes specific requirements for eligibility and submission. The solicitation encourages innovation and permits the use of consultants, underscoring the importance of leveraging expertise for impactful technological advancements. Overall, NCI aims to drive forward research that can significantly change clinical care for the specified cancer types through this funding opportunity.
    Attachment_1-Technical_Proposal_Form-NCI_SBIR_FY26_Concept_Award_Solicitation 3.pdf
    The Department of Health and Human Services outlines the submission requirements for the Small Business Innovation Research Program (SBIR) Phase I Concept Award proposals. Key components include a complete proposal cover sheet, technical proposal content covering various sections such as problem identification, technological solutions, innovation, methodology, and potential commercial applications. Offerors must certify their status as a small business and disclose any prior related federal funding. The proposal should detail resources, authentication of key biological or chemical resources, and a scientific data sharing plan to ensure transparency and compliance with NIH policies. Submissions must also include a Statement of Work that outlines technical objectives, milestones, and timelines while providing a concise overview of the technology's significance in addressing unmet medical needs in rare or pediatric cancers. Additionally, offerors must participate in the I-Corps™ program at NIH, enhancing their understanding of customer discovery and technology commercialization. This structured approach aims to foster innovation and develop viable solutions for serious health issues, reinforcing the program's commitment to advancing public health through small business contributions.
    FY26 SBIR Concept Solicitation - Updated by SEED.pdf
    The National Cancer Institute (NCI) is inviting proposals from small businesses for its Small Business Innovation Research (SBIR) Innovative Concept Award Program. Proposals should address the development of transformative technologies, particularly for pediatric and rare cancers with low survival rates. Key deadlines include a white paper submission by July 11, 2025, and full proposals by October 17, 2025. The NCI will evaluate submissions based on scientific feasibility, commercial potential, and if prior experience aligns with the required benchmarks. A significant focus of this program is the inclusion of a new proposal requirement: disclosure of any foreign relationships which must be submitted with the proposal. Funded proposals will undergo a three-phase program: Phase I focused on feasibility and proof-of-concept, Phase II for full R&D efforts, and Phase III aimed at commercialization without SBIR funding. Participation in the I-Corps™ program is also encouraged to enhance commercialization efforts. Overall, this initiative seeks to stimulate innovation in health-related research through active engagement and support for small business concerns, contributing to advancements in cancer diagnosis and treatment.
    Similar Opportunities
    Support for Evaluating and Conducting Computational and Alternative Toxicological Methods for the National Institute of Environmental Health Sciences
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institute of Environmental Health Sciences (NIEHS), is seeking proposals from small businesses to support the evaluation and conduct of computational and alternative toxicological methods. The objective of this procurement is to assist NIEHS in chemical hazard and risk assessment while minimizing the use of animal testing, focusing on areas such as population variability, developmental neurotoxicity, and carcinogenicity. This contract, which is a Cost-Plus-Fixed-Fee type, has a base period of performance from June 1, 2026, to May 31, 2027, with nine additional one-year options and a potential six-month extension. Proposals are due by December 19, 2025, and must be submitted electronically via the NIH eCPS website; interested parties can contact Jason Williams at jason.williams2@nih.gov or Lisa Schaupp at lisa.schaupp@nih.gov for further information.
    FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY26 Broad Agency Announcement (BAA) for advanced research and development in regulatory science. This opportunity aims to acquire basic and applied research that supports regulatory science and innovation, focusing on areas such as New Approach Methodologies, Advanced Manufacturing, and Clinical Outcome Assessments, among others. The FDA's initiative is crucial for enhancing scientific knowledge that aids in protecting and promoting public health, particularly for underrepresented populations and in reducing animal testing. Interested parties, including small businesses and academic institutions, are encouraged to submit proposals by February 24, 2026, and can reach out to Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases
    Health And Human Services, Department Of
    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking industry partners for clinical research collaborations focused on therapeutics, diagnostics, or devices for childhood cholestatic liver diseases. The initiative aims to engage collaborators in providing novel therapeutic agents and diagnostic tools for use in NIH-sponsored multi-center clinical trials targeting conditions such as biliary atresia and alpha-one antitrypsin deficiency, among others. This collaboration is critical for advancing research and improving clinical outcomes for children suffering from these rare liver diseases. Interested organizations must submit a Capability Statement detailing their proposed solutions and capabilities, with no funding provided by NIDDK for this opportunity. For inquiries, contact Edward Doo at dooe@niddk.nih.gov or Katrina Loh at katrina.loh@nih.gov.
    Inflammatory and Vascular Diseases Scientific Support
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a contract for Inflammatory and Vascular Diseases Scientific Support to Exonova Biosciences. The procurement aims to secure the services of a highly qualified scientist with extensive expertise in immunology and hereditary autoinflammatory diseases, who will contribute to the NIH's Biomedical and Metabolic Imaging Branch's research initiatives. This contract is crucial for advancing understanding in the fields of inflammation and vascular biology, particularly in relation to metabolic disorders, and is set to commence on January 1, 2026, with a performance period extending through December 31, 2026. Interested parties must respond by December 15, 2025, and can direct inquiries to Kimesha Leake at Kimesha.leake@nih.gov.
    Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the "Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)" program. This initiative aims to accelerate the development of innovative precision genetic medicines (PGMs) to treat hereditary rare diseases, focusing on creating integrated platforms that address technical and real-world challenges in genetic medicine. Proposals must include a solution summary, a PowerPoint presentation, and a detailed Gantt chart, with key deadlines set for October 31, 2025, for solution summaries and December 22, 2025, for PowerPoint submissions. Interested parties can contact the THRIVE Program at THRIVE@arpa-h.gov for further information.
    Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Innovative Solutions Opening (ISO) under the Scalable Solutions Office (SSO). This initiative aims to develop innovative solutions that enhance healthcare access, affordability, and distribution, particularly in underserved communities, while addressing challenges in biomanufacturing and health technology distribution. The solicitation is open until March 5, 2029, and encourages submissions from academia, non-profits, and for-profit entities, with multiple awards anticipated as Other Transactions. Interested parties must submit a Solution Summary for initial feedback before proceeding with a full proposal, adhering to strict guidelines on intellectual property, research security, and cost proposal requirements. For further details, proposers can reach out through the designated submission portals and must ensure compliance with the updated administrative and national policy requirements outlined in the solicitation documents.
    GENETIC MEDICINES AND INDIVIDUALIZED MANUFACTURING FOR EVERYONE (GIVE)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. This initiative aims to revolutionize the biomanufacturing of RNA-based genetic medicines by fostering innovations in automated RNA manufacturing and integrated quality control, ultimately enabling rapid, cost-effective, and localized production in non-GMP environments. Interested parties must submit solution summaries by December 19, 2025, with full proposals due by February 27, 2026, and are encouraged to participate in a Proposers’ Day on November 13, 2025, for further insights. For additional information, please refer to the program's website or contact the designated email address.
    Biospecimen Core Resource
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) under the National Cancer Institute (NCI), is seeking to establish a Biospecimen Core Resource (BCR) to support various biospecimen-related activities. The BCR will operate under documented Standard Operating Procedures (SOPs) to facilitate the collection, processing, distribution, and storage of biospecimens as outlined in NCI Task Orders. This initiative is crucial for advancing cancer research and ensuring the integrity and availability of biospecimens for scientific studies. Interested parties can reach out to Apisit Viriya at apisit.viriya@nih.gov or Mataya Robinson at mataya.robinson@nih.gov for further details regarding this opportunity.
    Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO). This opportunity invites submissions that address systemic challenges in healthcare and public health by leveraging innovative technologies to improve care quality, efficacy, and accessibility. Proposals will be evaluated based on scientific merit, alignment with ARPA-H's mission, proposer capabilities, and cost, with a focus on open-source intellectual property and compliance with research regulations. Interested parties must submit solution summaries and proposals via the designated ARPA-H portal, with the closing date for submissions set for March 5, 2029. For further inquiries, proposers can reach out through the same portal.
    NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is seeking information regarding an Electronic Document Management System (EDMS) for the Frederick National Laboratory for Cancer Research (FNLCR), which is operated by Leidos Biomedical Research, Inc. The EDMS aims to centralize and enhance the control and maintenance of construction project documentation for the Facilities, Maintenance, and Engineering (FME) Directorate, thereby improving collaboration among project teams and facilitating reporting for lessons learned and metrics. This initiative is crucial for streamlining documentation processes and may expand to other directorates in the future. Interested parties should submit their responses by January 9, 2026, and direct any inquiries to Cody Wenner at cody.wenner@nih.gov.